Zhejiang Shengda Pharm (603079) - Total Assets
Based on the latest financial reports, Zhejiang Shengda Pharm (603079) holds total assets worth CN¥2.19 Billion CNY (≈ $320.83 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 603079 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Zhejiang Shengda Pharm - Total Assets Trend (2012–2025)
This chart illustrates how Zhejiang Shengda Pharm's total assets have evolved over time, based on quarterly financial data. See Zhejiang Shengda Pharm net assets for net asset value and shareholders' equity analysis.
Zhejiang Shengda Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Shengda Pharm's total assets of CN¥2.19 Billion consist of 46.0% current assets and 54.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.8% |
| Accounts Receivable | CN¥152.83 Million | 7.0% |
| Inventory | CN¥189.74 Million | 8.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥222.94 Million | 10.1% |
| Goodwill | CN¥10.91 Million | 0.5% |
Asset Composition Trend (2012–2025)
This chart illustrates how Zhejiang Shengda Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603079 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Shengda Pharm's current assets represent 46.0% of total assets in 2025, an increase from 43.5% in 2012.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, up from 14.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 25.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 10.1% of total assets.
Zhejiang Shengda Pharm Competitors by Total Assets
Key competitors of Zhejiang Shengda Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Northeast Pharmaceutical Group Co Ltd
SHE:000597
|
China | CN¥13.59 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789
|
China | CN¥9.88 Billion |
Zhejiang Shengda Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.69 | 2.96 | 2.14 |
| Quick Ratio | 3.64 | 2.04 | 1.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥775.94 Million | CN¥439.03 Million | CN¥522.24 Million |
Zhejiang Shengda Pharm - Advanced Valuation Insights
This section examines the relationship between Zhejiang Shengda Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.89 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 23.1% |
| Total Assets | CN¥2.20 Billion |
| Market Capitalization | $324.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Shengda Pharm's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zhejiang Shengda Pharm's assets grew by 23.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zhejiang Shengda Pharm (2012–2025)
The table below shows the annual total assets of Zhejiang Shengda Pharm from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $321.72 Million |
+23.15% |
| 2024-12-31 | CN¥1.79 Billion ≈ $261.25 Million |
+3.85% |
| 2023-12-31 | CN¥1.72 Billion ≈ $251.57 Million |
+3.87% |
| 2022-12-31 | CN¥1.66 Billion ≈ $242.21 Million |
-6.21% |
| 2021-12-31 | CN¥1.76 Billion ≈ $258.25 Million |
+3.76% |
| 2020-12-31 | CN¥1.70 Billion ≈ $248.89 Million |
+10.98% |
| 2019-12-31 | CN¥1.53 Billion ≈ $224.27 Million |
+22.34% |
| 2018-12-31 | CN¥1.25 Billion ≈ $183.31 Million |
+27.05% |
| 2017-12-31 | CN¥985.98 Million ≈ $144.28 Million |
+32.99% |
| 2016-12-31 | CN¥741.37 Million ≈ $108.49 Million |
+18.78% |
| 2015-12-31 | CN¥624.13 Million ≈ $91.33 Million |
+13.84% |
| 2014-12-31 | CN¥548.27 Million ≈ $80.23 Million |
+8.55% |
| 2013-12-31 | CN¥505.09 Million ≈ $73.91 Million |
-0.46% |
| 2012-12-31 | CN¥507.42 Million ≈ $74.25 Million |
-- |
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.